Taxotere, Docetaxel

Taxotere, Docetaxel Newswire (Page 9)

Comprehensive Real-Time News Feed for Taxotere, Docetaxel (generic). (Page 9)

Results 161 - 180 of 845 in Taxotere, Docetaxel (generic)

  1. New Market Research Report: NanoCarrier Co., Ltd. (4571) - Financial...Read the original story

    Nov 4, 2014 | PR-inside.com

    The company researches, develops and produces pharmaceuticals using micellar nanoparticles technology. It develops drugs in the field of oncology.

    Comment?

  2. BIND Therapeutics Appoints Hagop Youssoufian, M.Sc., M.D. as Chief Medical OfficerRead the original story

    Nov 4, 2014 | Business Wire

    BIND Therapeutics, Inc. , a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced the appointment of Hagop Youssoufian, M.Sc., M.D., as Chief Medical Officer. In this position, Dr. Youssoufian will be responsible for overseeing the clinical development and operations of BIND's internal pipeline.

    Comment?

  3. Medivation, Inc. And Astellas Pharma US Announce Phase 3 Study Of...Read the original story

    Oct 31, 2014 | BioSpace

    Medivation Inc. and Astellas today announced plans to initiate a global Phase 3 clinical trial that will evaluate the efficacy and safety of enzalutamide in patients with high-risk, hormone-sensitive, non-metastatic prostate cancer that has biochemically recurred following definitive local therapy with radical prostatectomy and/or radiation therapy. Currently there is no prescription medicine specifically approved in the United States for these patients.

    Comment?

  4. BIND Therapeutics Announces Availability Of Abstract With Preliminary ...Read the original story

    Oct 30, 2014 | BioSpace

    BIND Therapeutics, Inc. , a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced the online availability of an abstract providing preliminary data from the Q3W arm of its ongoing Phase 2 study of BIND-014 in non-small cell lung cancer . Data included in the abstract were current as of the submission deadline on June 13, 2014 and updated data will be presented in a poster presentation on November 19, 2014 at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

    Comment?

  5. BIND Therapeutics to Present at November Healthcare ConferencesRead the original story

    Oct 29, 2014 | Freshnews

    BIND Therapeutics, Inc. , a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the following healthcare conferences during November 2014: Stifel Nicolaus Weisel Healthcare Conference 2014 in New York on Wednesday, November 19, 2014 at 8:35 a.m. EST. Interested parties may access a live webcast of the presentation by visiting the BIND Therapeutics website at www.bindtherapeutics.com .

    Comment?

  6. BIND Therapeutics to Present at November Healthcare ConferencesRead the original story

    Oct 29, 2014 | Business Wire

    BIND Therapeutics, Inc. , a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the following healthcare conferences during November 2014: Stifel Nicolaus Weisel Healthcare Conference 2014 in New York on Wednesday, November 19, 2014 at 8:35 a.m. EST. Interested parties may access a live webcast of the presentation by visiting the BIND Therapeutics website at www.bindtherapeutics.com .

    Comment?

  7. Astellas Pharma Inc.'s XTANDI??? (Enzalutamide) Capsules Receive...Read the original story

    Oct 24, 2014 | BioSpace

    Astellas Pharma Inc. 's XTANDIa Capsules Receive Positive CHMP Opinion For The Treatment Of Men With Metastatic Castration-Resistant Prostate Cancer Who Are Chemotherapy-NaA ve CHERTSEY, England-- --Astellas Pharma Europe Ltd. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a variation to amend the Marketing Authorisation for enzalutamide .

    Comment?

  8. XTANDIa (Enzalutamide) Capsules Receive Positive CHMP Opinion for the ...Read the original story

    Oct 24, 2014 | Business Wire

    XTANDI a Capsules Receive Positive CHMP Opinion for the Treatment of Men with Metastatic Castration-Resistant Prostate Cancer Who Are Chemotherapy-NaA ve CHERTSEY, England-- --Astellas Pharma Europe Ltd. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a variation to amend the Marketing Authorisation for enzalutamide .

    Comment?

  9. XTANDIa (Enzalutamide) Capsules Receive Positive CHMP Opinion for...Read the original story

    Oct 24, 2014 | Business Wire

    XTANDI a Capsules Receive Positive CHMP Opinion for the Treatment of Men with Metastatic Castration-Resistant Prostate Cancer Who Are Chemotherapy-NaA ve CHERTSEY, England-- --Astellas Pharma Europe Ltd. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a variation to amend the Marketing Authorisation for enzalutamide .

    Comment?

  10. BIND Therapeutics to Report Third Quarter 2014 Financial Results on November 6, 2014Read the original story

    Oct 23, 2014 | Freshnews

    BIND Therapeutics, Inc. , a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced it will report third quarter 2014 financial results on Thursday, November 6, 2014. BIND's management team will host a conference call and audio webcast on Thursday, November 6, 2014 at 8:30 a.m. Eastern Time to discuss the quarterly results and recent business developments.

    Comment?

  11. CDC Issues New Ebola Treatment ProtocolsRead the original story

    Oct 21, 2014 | P&T Community

    The Centers for Disease Control and Prevention has tightened its previous infection-control guidance for health care workers caring for patients with Ebola. The guidance now focuses on specific personal protective equipment that health care workers should use and offers detailed instructions for how to put the equipment on and take it off safely.

    Comment?

  12. Boehringer Ingelheim initiates global Phase III study investigating...Read the original story

    Oct 21, 2014 | PressReleasePoint

    Colorectal cancer is the third most common cancer in the world, with nearly 1.4 million new cases diagnosed each year.3 Prognosis is poor for patients with advanced CRC with fewer than 10% surviving for more than five years after diagnosis.3 LUME-COLON 1 [ClinicalTrials.gov identifier: NCT02149108] is a double-blind, randomised, placebo-controlled study designed to evaluate the efficacy and safety of nintedanib* plus best supportive care , versus placebo plus BSC, after previous treatment with standard chemotherapy and biological agents.1 This new study builds on the early efficacy signs observed with nintedanib* in CRC during Phase I/II trials.4,5 "There is a significant need to improve treatment options for patients with advanced colorectal cancer and Boehringer Ingelheim is proud to conduct further research into this disease area.

    Comment?

  13. Boehringer Ingelheim initiates global Phase III study investigating...Read the original story

    Oct 21, 2014 | Business Wire

    The initiation of LUME-COLON 1 reinforces our ongoing commitment to driving innovation in oncology research" Boehringer Ingelheim today announced the enrolment of the first patient in a new global Phase III study in patients with advanced colorectal cancer . Colorectal cancer is the third most common cancer in the world, with nearly 1.4 million new cases diagnosed each year.

    Comment?

  14. Computer Simulation May Shape Antibiotics of the FutureRead the original story

    Oct 17, 2014 | P&T Community

    Scientists in the United Kingdom have used computer simulations to show how bacteria are able to destroy antibiotics - a breakthrough that will help develop drugs to tackle infections effectively in the future. Researchers at the University of Bristol focused on the role of enzymes in the bacteria, which split the structure of the antibiotic and stop it from working, making the bacteria resistant.

    Comment?

  15. 'Spray-On Skin' for Leg Ulcers Flops in Clinical TrialRead the original story

    Oct 12, 2014 | P&T Community

    Disappointing results have been announced from a phase III study of HP802-247 , a living-cell spray-on therapy designed to work with the body's own cells to stimulate healing of venous leg ulcers . HP802-247 did not meet the study's primary endpoint - a statistically significant improvement in healing - compared with placebo in the randomized, double-blind, vehicle-controlled study, conducted in North America.

    Comment?

  16. Molecular characterisation of isogenic taxane resistant cell lines...Read the original story

    Oct 13, 2014 | BioMed Central

    Taxanes such as paclitaxel and docetaxel are used successfully to treat breast cancer, usually in combination with other agents. They interfere with microtubules causing cell cycle arrest; however, the mechanisms underlying the clinical effects of taxanes are yet to be fully elucidated.

    Comment?

  17. Golemiec first to receive regular treatment with new drugRead the original story

    Oct 9, 2014 | Truro Daily News

    Mine was filled with anticipation. It's that week, the one I've been getting ready for.

    Comment?

  18. Phyton Biotech Launches New WebsiteRead the original story

    Oct 7, 2014 | Freshnews

    Phyton Biotech, the pioneer in plant cell fermentation technology with the world's largest capacity for paclitaxel and docetaxel API via PCF, has launched a new website: www.phytonbiotech.com . The new website maintains Phyton's commitment to being the best commercial supplier of paclitaxel and docetaxel API in the world and also emphasizes Phyton's increased focus on Development Services for plant-derived actives via PCF and for complex small molecules.

    Comment?

  19. Rexahn's New Nanotechnology Patent Creates Next-Generation Docetaxel, Gemcitabine And CisplatinRead the original story w/Photo

    Oct 7, 2014 | Seeking Alpha

    Targeted cancer therapy is a revolution in drug company research, and Rexahn Pharmaceuticals, Inc. , recent recipient of a notice of allowance from the US Patent and Trademark Office for a new delivery platform, might one day join the league of bigger players. Chemotherapy cocktails, a standard in past years, have proven suboptimal with poisonous side effects.

    Comment?

  20. BIND Therapeutics, Inc. - Pharmaceuticals & Healthcare - Deals and...Read the original story

    Oct 7, 2014 | PR-inside.com

    The company develops and commercializes preclinical candidates for cancer, cardiovascular disease, and inflammatory disease. BIND Therapeutics develops Accurins.

    Comment?